Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

New guide to help cancer patients manage symptoms, side effects

Cancer patients can be hit with a nasty array of symptoms and side effects, from anemia and anxiety to hair loss and hot flashes. Some of these problems can be so overwhelming that they cause patients to abandon life-saving treatments.

30 Apr 2011

IMPAKT 2011 conference to highlight new breast cancer studies

"The presentations at this year's IMPAKT reveal the innovative and diverse approaches that investigators are taking to identify the most encouraging new agents both before clinical evaluation and in early clinical studies. These range from ideas for novel clinical designs to the development of more sensitive and specific biomarkers and to data sharing that allows a more objective assessment of compounds prior to commitment of major clinical resources."

30 Apr 2011

Spectrum receives FDA approval for FUSILEV to treat colorectal cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, received approval from the U.S. Food and Drug Administration on April 29, 2011, for the use of FUSILEV in combination with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer.

30 Apr 2011

Annual mammogram sufficient follow-up after BCT for breast cancer patients

An annual mammogram is sufficient follow-up after breast conserving therapy (BCT) for breast cancer patients, according to a study presented today, at the Cancer Imaging and Radiation Therapy Symposium in Atlanta. This symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO) and Radiological Society of North America (RSNA).

29 Apr 2011

Proton radiography imaging helps lower radiation dosage to pediatric cancer patients

Proton radiography imaging used prior to and during proton treatments for pediatric cancer patients provides for more accurate treatment delivery and a lower dose of radiation compared to standard diagnostic X-rays and cone beam CT, according to a study presented today at the Cancer Imaging and Radiation Therapy Symposium in Atlanta. The symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO) and the Radiological Society of North America (RSNA).

29 Apr 2011

Pelvic MRI scan identifies local recurrence of prostate cancer at low PSA levels

A pelvic MRI scan with IV contrast and rectal balloon is highly effective in identifying local recurrence even at low PSA values in prostate cancer patients with a rising or persistently elevated PSA after prostatectomy, according to a study presented April 29, 2011, at the Cancer Imaging and Radiation Therapy Symposium in Atlanta. The symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO) and the Radiological Society of North America (RSNA).

29 Apr 2011

Injecting tissue spacers reduces risk of radiation burns to rectum in prostate cancer patients

Injecting a tissue spacer in the prostate-rectal inter-space is an effective way to reduce the rectal dose for prostate cancer patients receiving radiation therapy, according to research presented April 30, 2011, at the Cancer Imaging and Radiation Therapy Symposium in Atlanta. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO) and Radiological Society of North America (RSNA).

29 Apr 2011

Bayer expands sponsorship agreement with World Federation of Hemophilia

Bayer HealthCare Pharmaceuticals and the World Federation of Hemophilia are announcing a three-year extension of Bayer's sponsorship agreement with WFH.

29 Apr 2011

Biodesix announces patient enrollment for VeriStrat CASTLE study in lung cancer

Biodesix announces the enrollment of initial subjects into CASTLE, the inaugural study of the Addario Lung Cancer Medical Institute.

29 Apr 2011

MorphoSys reaches second clinical milestone with OncoMed Pharmaceuticals

MorphoSys AG announced today that it has received a milestone payment from OncoMed Pharmaceuticals in connection with the FDA acceptance of an IND for a HuCAL-derived, fully human antibody. The antibody OMP-18R5, which targets the Wnt signaling pathway, will be evaluated in a Phase 1 trial in the US in patients with advanced solid tumors.

29 Apr 2011

Experts to present stem cell therapies for neurological disorders at Cedars-Sinai conference

Experts from stem cell programs at respected research centers around the country will present information at an April 30 conference on stem cell therapy for neurological disorders, hosted by the Department of Neurosurgery at Cedars-Sinai Medical Center in collaboration with the Genetics Policy Institute of Wellington, Fla.

29 Apr 2011

New PET imaging clinical trial to improve early esophageal, lung cancer detection

Can a simple imaging test help predict the success of cancer treatment, even before the treatment is complete? To begin to answer this question, a new National Cancer Institute-funded clinical trial is using a novel PET imaging technique that could improve the early detection of tumor growth during treatment for esophageal and lung cancer.

29 Apr 2011

CEL-SCI initiates Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Meenakshi Mission Hospital and Research Centre in Madurai, Tamil Nadu, India, the first clinical site in India.

28 Apr 2011

Roche introduces new Accu-Chek Mobile glucose monitoring device

Roche Diagnostics Canada, a trailblazer in the healthcare field, is proud to introduce Accu-Chek Mobile, the first strip-free blood glucose monitoring device available on the market.

From Roche Sequencing and Life Science 28 Apr 2011

Centocor Ortho Biotech receives FDA approval for Zytiga to treat prostate cancer

The U.S. Food and Drug Administration today approved Zytiga in combination with prednisone to treat patients with late-stage castration-resistant prostate cancer who have received prior docetaxel.

28 Apr 2011

Nautic Partners announces acquisition of Omnicare Clinical Research

Nautic Partners LLC, a private equity firm with more than $2.5 billion of capital under management, today announced that it has acquired Omnicare Clinical Research from Omnicare, Inc. Headquartered in King of Prussia, PA, Omnicare CR is a full-service, global clinical research organization.

28 Apr 2011

FDA approves orphan drug designation for Cytrx’s INNO-206 to treat pancreatic cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its tumor-targeting pro-drug candidate INNO-206 has been approved for orphan drug designation for the treatment of patients with pancreatic cancer by the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA). CytRx holds the exclusive worldwide development and commercialization rights to INNO-206.

28 Apr 2011